Sobajima Satoshi, Vadala Gianluca, Shimer Adam, Kim Joseph S, Gilbertson Lars G, Kang James D
Spine Research Laboratory, Department of Orthopedic Surgery, University of Pittsburgh School of Medicine, 200 Lothrop Street, C-313 PUH, Pittsburgh, PA 15213, USA.
Spine J. 2008 Nov-Dec;8(6):888-96. doi: 10.1016/j.spinee.2007.09.011. Epub 2007 Dec 21.
Different strategies to supplement/replenish the disc cell population have been proposed. Recently, adult stem cells have shown promise as a cell source for a variety of tissue engineering and cell therapy applications. A stem cell can renew itself through cell division and can be induced to develop into many different specialized cell types. Moreover, stem cells have shown ability to migrate and engraft within various tissues, as well as to exert stimulatory effects on other cell types through various mechanisms (eg, paracrine effects, cell-cell interactions). These characteristics make stem cells worthy of investigation as a source of cells for intervertebral disc (IVD) tissue engineering and cell therapy.
To determine feasibility of a stem cell therapy of IVD degeneration.
In vitro studies of adult human cells to examine interactions between nucleus pulposus cells (NPCs) and mesenchymal stem cells (MSCs) at different ratios in 3-D pellet culture. In vivo studies of healthy adult rabbit discs injected with allogenic adult rabbit MSCs to examine stem cell survival and engraftment in living disc tissue.
In vitro study: Human NPCs were cocultured with human MSCs in different ratios (75:25, 50:50, 25:75) for 2 weeks in pellet culture, for comparison with pure NPC (100:0) and pure MSC (0:100) pellet cultures. Proteoglycan synthesis rate and glycosaminoglycan (GAG) content were measured by radioactive sulfate incorporation and dimethylmethylene blue assay, respectively. In vivo study: MSCs were isolated from the bone marrow of a New Zealand White (NZW) rabbit, retrovirally transduced with the lacZ marker gene, and injected into the nucleus pulposi of the L2-3, L3-4, and L4-5 lumbar discs of 12 other NZW rabbits. Three rabbits each were sacrificed at 3, 6, 12, or 24 weeks after cell implantation, and X-Gal staining was done to assess survival and localization of MSCs in the disc tissues.
In vitro study: the 75:25 and 50:50 NPC:MSC cocultures yielded the greatest increases in extracellular matrix (ECM) production. In vivo study: MSCs were detected in histological sections of rabbit discs up to 24 weeks after allogenic stem cell implantation, without evidence of systemic illness in the recipient rabbits. The 24-week results in particular suggested the possibility of stem cell migration and engraftment into the inner annulus fibrosus.
These encouraging results support feasibility of a stem cell therapy approach toward supplementation/replenishment of IVD cells and synthesis/maintenance of a more functional ECM in a degenerated disc. Moreover, the in vivo results demonstrate that transplanted MSCs survive and successfully engraft into the IVD tissue, and are effective vehicles for exogenous gene delivery to the IVD--thus there appear to be multiple mechanisms whereby stem cells might able to confer therapeutic effects in a stem cell therapy of IVD degeneration.
已提出多种补充/ replenish椎间盘细胞群的策略。近来,成体干细胞作为多种组织工程和细胞治疗应用的细胞来源显示出前景。干细胞可通过细胞分裂自我更新,并可被诱导发育为多种不同的特化细胞类型。此外,干细胞已显示出在各种组织内迁移和植入的能力,以及通过多种机制(如旁分泌效应、细胞 - 细胞相互作用)对其他细胞类型发挥刺激作用的能力。这些特性使干细胞作为椎间盘(IVD)组织工程和细胞治疗的细胞来源值得研究。
确定干细胞治疗IVD退变的可行性。
对成人细胞进行体外研究,以检查在三维微球培养中不同比例的髓核细胞(NPCs)和间充质干细胞(MSCs)之间的相互作用。对健康成年兔椎间盘进行体内研究,注射同种异体成年兔MSCs,以检查干细胞在活椎间盘组织中的存活和植入情况。
体外研究:人NPCs与人MSCs以不同比例(75:25、50:50、25:75)在微球培养中共培养2周,与纯NPC(100:0)和纯MSC(0:100)微球培养作比较。分别通过放射性硫酸盐掺入法和二甲基亚甲蓝测定法测量蛋白聚糖合成率和糖胺聚糖(GAG)含量。体内研究:从新西兰白兔(NZW)的骨髓中分离MSCs,用lacZ标记基因进行逆转录病毒转导,并注入另外12只NZW兔的L2 - 3、L3 - 4和L4 - 5腰椎间盘的髓核中。在细胞植入后3、6、12或24周,每组3只兔被处死,进行X - Gal染色以评估MSCs在椎间盘组织中的存活和定位。
体外研究:75:25和50:50的NPC:MSC共培养使细胞外基质(ECM)产生增加最多。体内研究:在同种异体干细胞植入后长达24周的兔椎间盘组织学切片中检测到MSCs,受体兔无全身疾病迹象。特别是24周的结果提示干细胞迁移并植入内层纤维环的可能性。
这些令人鼓舞的结果支持了干细胞治疗方法在补充/ replenish IVD细胞以及在退变椎间盘中合成/维持更具功能的ECM方面的可行性。此外,体内结果表明移植的MSCs存活并成功植入IVD组织,并且是向IVD进行外源基因递送的有效载体——因此在IVD退变的干细胞治疗中,干细胞似乎有多种机制可发挥治疗作用。